NCT07201051

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.

Conditions

• Bronchiectasis

Interventions

Type	Name	Description
DRUG	GSK3862995B	Participants will be administered with dose level 1 of GSK3862995B.
DRUG	Placebo	Participants will be administered with matching placebo.

Timeline

• Start date: 2025-09-26
• Primary completion: 2027-03-15
• Completion: 2027-11-08
• First posted: 2025-10-01
• Last updated: 2025-10-01

Regulatory

• FDA-regulated drug study